01—Abstract
Summary
Summary of the 8-K filed May 1, 2024. Cited figures are marked; the original filing is the authoritative source.
Pfizer reported first-quarter 2024 results on May 1, 2024, with revenues of $14.9 billiona, down 20% reported and 19% operationally from $18.5 billion a year earlier.
The decline was driven by a steep drop in COVID-19 products: Comirnaty revenues fell 88% operationally to $354 millionb and Paxlovid fell 50% to $2.0 billion. Excluding those two products, revenues grew 11% operationally to $12.5 billion, supported by legacy Seagen contributions ($742 million), Vyndaqel family growth (up 66%), Eliquis (up 10%), Abrysvo, and Prevnar family (up 7%). Reported diluted EPS was $0.55 (down 44%), and Adjusted diluted EPS was $0.82 (down 33%).
Both figures include a $0.11c favorable one-time impact from a $771 million Paxlovid revenue reversal adjustment. Management reaffirmed full-year 2024 revenue guidance of $58.5 to $61.5 billion and raised Adjusted diluted EPS guidance to $2.15 to $2.35, up from $2.05 to $2.25. The company remains on track for at least $4 billion in net cost savings by year-end 2024 under its cost realignment program.
Guidance assumes roughly 90% of Comirnaty sales occur in the second half, largely in the fourth quarter, reflecting COVID vaccine seasonality. Capital returned to shareholders included $2.4 billiond in dividends ($0.42 per share), with no share repurchases made in 2024 to date and none anticipated under current guidance.
For investors, the key takeaways are the strength of the non-COVID portfolio and the margin benefit from lower COVID product mix, offset by higher net interest expense following the Seagen acquisition and a sharp decline in total reported revenue. The quarter's reported GAAP results were weighed down by amortization, interest costs, and legal and Haleon-related items, so Adjusted measures paint a more favorable picture than GAAP figures.
02—Key points
Key Highlights
- Total revenues of $14.9 billion, down 20% reported (19% operationally), primarily due to the expected decline in Comirnaty (down 88% operationally) and Paxlovid (down 50%).
- Revenues excluding Comirnaty and Paxlovid grew 11% operationally to $12.5 billion, showing solid growth in the non-COVID portfolio.
- Reported diluted EPS of $0.55 (down 44%) and Adjusted diluted EPS of $0.82 (down 33%); both include a $0.11 benefit from a $771 million Paxlovid revenue reversal adjustment.
- Full-year 2024 revenue guidance reaffirmed at $58.5 to $61.5 billion; Adjusted diluted EPS guidance raised to $2.15 to $2.35 from $2.05 to $2.25.
- On track to deliver at least $4 billion in net cost savings by end of 2024 under the cost realignment program.
- Cost of sales as a percentage of revenue fell to 22.7% (reported) from 26.4%, aided by lower Comirnaty sales mix and the Paxlovid adjustment.
- Net interest expense rose sharply to $661 million from $141 million, reflecting debt issued for the Seagen acquisition; no share repurchases in 2024 to date, with $3.3 billion remaining authorization.
03—Questions
Frequently Asked Questions
Why did Pfizer's revenue decline so sharply in Q1 2024?
The decline was driven mainly by COVID-19 products. Comirnaty revenue fell $2.7 billion (88% operationally) due to lower contractual deliveries, lower demand, and the transition to commercial market sales. Paxlovid revenue fell $2.0 billion (50%) for similar reasons, plus a non-recurring surge in China in early 2023. Excluding these two products, revenue actually grew 11%.
Did Pfizer change its 2024 financial outlook?
Yes, partially. Revenue guidance of $58.5 to $61.5 billion was reaffirmed, while Adjusted diluted EPS guidance was raised to $2.15 to $2.35 from $2.05 to $2.25. The raise reflects confidence in the cost realignment program and the underlying business strength. Other guidance components, including SI&A and R&D expense ranges, were maintained.
How much of Pfizer's Q1 2024 earnings came from one-time items?
The $771 million favorable final adjustment to the Paxlovid revenue reversal added about $0.11 to both reported and Adjusted diluted EPS. Investors should note this as a non-recurring benefit that flatters the quarter's results.
What is Pfizer doing with its capital and shareholder returns?
In Q1 2024, Pfizer invested $2.5 billion in internal R&D and about $100 million in business development, and paid $2.4 billion in cash dividends ($0.42 per share). No share repurchases were made in 2024 to date, and guidance assumes none for the year. Remaining buyback authorization stands at $3.3 billion.
Why did GAAP net income fall more than Adjusted results?
GAAP net income fell 44% to $3.1 billion, while Adjusted income fell 34% to $4.7 billion. The gap reflects excluded items such as $1.3 billion of intangible asset amortization, acquisition-related costs, and legal matters, along with a higher GAAP effective tax rate of 8.6% versus 16.6% on an Adjusted basis.
04—Continue